Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies-Reference-Cited by-同舟云学术

Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies

Published:2024-06-29 Issue:1 Volume:10 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Cheang Maggie Chon U,Rimawi Mothaffar^ORCID,Johnston Stephen,Jacobs Samuel A.,Bliss Judith,Pogue-Geile Katherine,Kilburn Lucy,Zhu Zhou,Schuster Eugene F.,Xiao Hui,Swaim Lisa,Deng Shibing,Lu Dongrui R.,Gauthier Eric^ORCID,Tursi Jennifer,Slamon Dennis J.,Rugo Hope S.^ORCID,Finn Richard S.^ORCID,Liu Yuan

Abstract

AbstractIntrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used.Trial number: NCT01740427

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41523-024-00658-y.pdf

Reference24 articles.

1. Rugo, H. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J. Clin. Oncol. 34, 3069–3103 (2016).

2. Thomssen, C., Balic, M., Harbeck, N. & Gnant, M. St. Gallen/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Breast Care (Basel) 16, 135–143 (2021).

3. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).

4. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).

5. Carey, L. A. et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J. Clin. Oncol. 34, 542–549 (2016).